Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence.

about

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience

P2860

Q58756156-F07785E1-18AC-41A8-AFF7-7D880B79A9CE

P2860

Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence.

Item

http://www.wikidata.org/entity/Q46650963

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Effectiveness and Safety of Di ...... Patients: Real-World Evidence.

@en

Effectiveness and Safety of Di ...... Patients: Real-World Evidence.

@nl

type

Item

label

Effectiveness and Safety of Di ...... Patients: Real-World Evidence.

@en

Effectiveness and Safety of Di ...... Patients: Real-World Evidence.

@nl

prefLabel

Effectiveness and Safety of Di ...... Patients: Real-World Evidence.

@en

Effectiveness and Safety of Di ...... Patients: Real-World Evidence.

@nl

P1476

Effectiveness and Safety of Di ...... Patients: Real-World Evidence

@en

P2093

Jasem Al-Hashel

http://www.w3.org/2001/XMLSchema#string

Raed Alroughani

http://www.w3.org/2001/XMLSchema#string

Raed Behbehani

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

Effect of relapses on development of residual deficit in multiple sclerosis.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Dimethyl fumarate associated lymphopenia in clinical practice.

Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.

Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.

Fingolimod after natalizumab and the risk of short-term relapse.

Effects of dimethyl fumarate on lymphocyte subsets.

P2888

s40120-017-0080-x

P304

189-196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40120-017-0080-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Samar Farouk Ahmed

P577

2017-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28780745

http://www.w3.org/2001/XMLSchema#string

P932

5700902

http://www.w3.org/2001/XMLSchema#string

Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence.

about

P2860

P2860

Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932